Phathom Pharmaceuticals Announces Vonoprazan NDA Submission For Non-Erosive GERD
Portfolio Pulse from Bill Haddad
Phathom Pharmaceuticals has announced the submission of a New Drug Application (NDA) for Vonoprazan for the treatment of non-erosive gastroesophageal reflux disease (GERD).
September 26, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals' NDA submission for Vonoprazan could potentially lead to a new revenue stream if approved.
The submission of a New Drug Application (NDA) is a significant step towards the commercialization of a new drug. If approved, Vonoprazan could provide a new revenue stream for Phathom Pharmaceuticals, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100